Sanctuary Advisors LLC Acquires 40,951 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sanctuary Advisors LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 183,289 shares of the biopharmaceutical company’s stock after buying an additional 40,951 shares during the quarter. Sanctuary Advisors LLC’s holdings in Gilead Sciences were worth $16,531,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of GILD. Pine Valley Investments Ltd Liability Co bought a new position in Gilead Sciences in the third quarter valued at about $209,000. SkyView Investment Advisors LLC increased its position in shares of Gilead Sciences by 5.4% during the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company’s stock valued at $711,000 after purchasing an additional 435 shares during the last quarter. Tri Ri Asset Management Corp purchased a new position in shares of Gilead Sciences in the third quarter worth approximately $3,163,000. Westside Investment Management Inc. grew its position in Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company’s stock valued at $2,249,000 after buying an additional 917 shares during the period. Finally, Rehmann Capital Advisory Group increased its holdings in Gilead Sciences by 3.6% during the third quarter. Rehmann Capital Advisory Group now owns 9,626 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 333 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Oppenheimer boosted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 1.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 447,234 shares of company stock valued at $41,288,086 over the last 90 days. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $92.38 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The stock has a market capitalization of $115.13 billion, a P/E ratio of 1,026.44, a P/E/G ratio of 2.38 and a beta of 0.18. The business has a 50-day moving average price of $89.82 and a two-hundred day moving average price of $79.26.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 earnings per share. Equities analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.33%. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.